• Foundation
• People
• Programs
  • Healthspan Program KHARIS
  • Systems Genetics
  • Neurodegeneration Program ALS
  • Success Stories
• Copy of Projects
• News
• Contact
• ways to help
• how we work

June 2024

ReMedys is proud to announce that it has secured from EPFL a license to the Kharis platform. This agreement grants ReMedys the rights to translate the largest longitudinal mouse aging dataset in the world into biomarkers and management strategies for aging.

June 2024

We are proud to welcome Prof. Johan Auwerx to our Board of directors. As a Board member, Prof. Auwerx will lead our strategy and decisions on healthspan-related projects. 

March 2022

ReMedys secured financing for the preclinical phase of the ALS- gene therapy program.